Go Pro
→ Everyone remembers January's silver spike. Then what? (From i2i Marketing Group, LLC) (Ad)tc pixel Free GOSS Stock Alerts

Gossamer Bio (GOSS) Competitors

Gossamer Bio logo
$11.48 +0.49 (+4.44%)
As of 09:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

GOSS vs. OKUR, TLSA, PMN, ENGN, and CBUS

Should you buy Gossamer Bio stock or one of its competitors? Gossamer Bio's main competitors and comparable companies include OnKure Therapeutics (OKUR), Tiziana Life Sciences (TLSA), Promis Neurosciences (PMN), enGene (ENGN), and Cibus (CBUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gossamer Bio compare to OnKure Therapeutics?

Gossamer Bio (NASDAQ:GOSS) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Gossamer Bio had 17 more articles in the media than OnKure Therapeutics. MarketBeat recorded 19 mentions for Gossamer Bio and 2 mentions for OnKure Therapeutics. Gossamer Bio's average media sentiment score of 0.29 beat OnKure Therapeutics' score of -1.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company Overall Sentiment
Gossamer Bio Neutral
OnKure Therapeutics Negative

OnKure Therapeutics has lower revenue, but higher earnings than Gossamer Bio. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$48.47M0.69-$170.37M-$56.00N/A
OnKure TherapeuticsN/AN/A-$59.52M-$3.50N/A

OnKure Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-235.00% N/A -112.04%
OnKure Therapeutics N/A -49.01%-45.77%

Gossamer Bio presently has a consensus price target of $256.00, indicating a potential upside of 2,130.35%. OnKure Therapeutics has a consensus price target of $17.50, indicating a potential upside of 490.22%. Given Gossamer Bio's higher possible upside, research analysts plainly believe Gossamer Bio is more favorable than OnKure Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22
OnKure Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Gossamer Bio has a beta of 2, suggesting that its share price is 100% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by insiders. Comparatively, 2.2% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Gossamer Bio beats OnKure Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Tiziana Life Sciences has higher earnings, but lower revenue than Gossamer Bio.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life SciencesN/AN/A-$18.43MN/AN/A
Gossamer Bio$48.47M0.69-$170.37M-$56.00N/A

Tiziana Life Sciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2, meaning that its stock price is 100% more volatile than the broader market.

Tiziana Life Sciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Gossamer Bio -235.00%N/A -112.04%

In the previous week, Gossamer Bio had 8 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 19 mentions for Gossamer Bio and 11 mentions for Tiziana Life Sciences. Gossamer Bio's average media sentiment score of 0.29 beat Tiziana Life Sciences' score of 0.21 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tiziana Life Sciences
1 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gossamer Bio
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

81.2% of Gossamer Bio shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 4.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gossamer Bio has a consensus target price of $256.00, indicating a potential upside of 2,130.35%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tiziana Life Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Gossamer Bio
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22

Summary

Gossamer Bio beats Tiziana Life Sciences on 8 of the 12 factors compared between the two stocks.

How does Gossamer Bio compare to Promis Neurosciences?

Gossamer Bio (NASDAQ:GOSS) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Promis Neurosciences has lower revenue, but higher earnings than Gossamer Bio. Promis Neurosciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$48.47M0.69-$170.37M-$56.00N/A
Promis NeurosciencesN/AN/A-$39.72M-$8.54N/A

Promis Neurosciences has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-235.00% N/A -112.04%
Promis Neurosciences N/A -143.09%-109.15%

In the previous week, Gossamer Bio had 17 more articles in the media than Promis Neurosciences. MarketBeat recorded 19 mentions for Gossamer Bio and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.37 beat Gossamer Bio's score of 0.29 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Promis Neurosciences
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gossamer Bio has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

Gossamer Bio currently has a consensus price target of $256.00, suggesting a potential upside of 2,130.35%. Promis Neurosciences has a consensus price target of $34.00, suggesting a potential upside of 168.94%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Promis Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22
Promis Neurosciences
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.88

Summary

Gossamer Bio beats Promis Neurosciences on 8 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to enGene?

Gossamer Bio (NASDAQ:GOSS) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Gossamer Bio presently has a consensus target price of $256.00, suggesting a potential upside of 2,130.35%. enGene has a consensus target price of $11.05, suggesting a potential upside of 464.98%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts plainly believe Gossamer Bio is more favorable than enGene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22
enGene
2 Sell rating(s)
8 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.14

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by insiders. Comparatively, 10.5% of enGene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Gossamer Bio has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

enGene has lower revenue, but higher earnings than Gossamer Bio. enGene is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$48.47M0.69-$170.37M-$56.00N/A
enGeneN/AN/A-$117.30M-$1.13N/A

enGene has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat enGene's return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-235.00% N/A -112.04%
enGene N/A -27.97%-22.65%

In the previous week, Gossamer Bio had 9 more articles in the media than enGene. MarketBeat recorded 19 mentions for Gossamer Bio and 10 mentions for enGene. Gossamer Bio's average media sentiment score of 0.29 beat enGene's score of 0.07 indicating that Gossamer Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
enGene
0 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Gossamer Bio beats enGene on 9 of the 14 factors compared between the two stocks.

How does Gossamer Bio compare to Cibus?

Gossamer Bio (NASDAQ:GOSS) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Gossamer Bio has a beta of 2, indicating that its stock price is 100% more volatile than the broader market. Comparatively, Cibus has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

Gossamer Bio has a net margin of -235.00% compared to Cibus' net margin of -2,258.89%. Gossamer Bio's return on equity of 0.00% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Gossamer Bio-235.00% N/A -112.04%
Cibus -2,258.89%-287.03%-27.99%

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Gossamer Bio had 17 more articles in the media than Cibus. MarketBeat recorded 19 mentions for Gossamer Bio and 2 mentions for Cibus. Gossamer Bio's average media sentiment score of 0.29 beat Cibus' score of 0.18 indicating that Gossamer Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gossamer Bio
0 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cibus
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cibus has lower revenue, but higher earnings than Gossamer Bio. Cibus is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gossamer Bio$48.47M0.69-$170.37M-$56.00N/A
Cibus$3.64M32.86-$127.08M-$1.65N/A

Gossamer Bio presently has a consensus price target of $256.00, indicating a potential upside of 2,130.35%. Cibus has a consensus price target of $9.00, indicating a potential upside of 475.08%. Given Gossamer Bio's stronger consensus rating and higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Cibus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gossamer Bio
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Gossamer Bio beats Cibus on 11 of the 16 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GOSS vs. The Competition

Export
MetricGossamer BioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$33.53M$3.98B$7.31B$13.28B
Dividend YieldN/A3.63%2.52%12.56%
P/E Ratio-0.2013.88274.0725.70
Price / Sales0.691,441.33673.2290.62
Price / CashN/A113.2977.8052.76
Price / Book-0.2715.1710.386.32
Net Income-$170.37M-$22.82M$3.49B$359.73M
7 Day Performance-3.87%-1.72%-0.69%0.17%
1 Month Performance-18.01%-6.19%-3.19%-3.27%
1 Year Performance-95.20%30.62%15.12%5.58%

Gossamer Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GOSS
Gossamer Bio
2.8696 of 5 stars		$11.48
+4.4%		$256.00
+2,130.4%		-95.5%$33.53M$48.47MN/A162
OKUR
OnKure Therapeutics
2.5358 of 5 stars		$3.00
-3.2%		$17.50
+483.3%		+16.2%$125.23MN/AN/AN/A
TLSA
Tiziana Life Sciences
1.5362 of 5 stars		$0.89
-7.3%		N/A-40.3%$122.17MN/AN/A8
PMN
Promis Neurosciences
3.5612 of 5 stars		$13.26
-2.2%		$34.00
+156.4%		+26.1%$121.60MN/AN/A5
ENGN
enGene
3.9364 of 5 stars		$1.87
+3.9%		$11.05
+490.7%		-70.4%$120.57MN/AN/A31

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Arizona Gold Explorer Nears First-Ever Resource Estimate
A little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...
Wall Street Logic | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Congress Passes Landmark Digital Asset Law Wall Street Is Watching
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel